At a glance
ClinicalIndex Comparison Record- ✓Chronic bronchopulmonary aspergillosis confirmed by compatible chest imaging (CT scan) and/or endoscopic lesion with photo documentation
- ✓Complex aspergilloma that is non-primarily operable
- ✓Chronic necrotizing pulmonary aspergillosis
- ✓Tracheo-bronchial aspergillosis (obstructive or necrotizing/pseudo-membranous)
- ✕Risk factors for cardiac arrhythmia or symptomatic arrhythmia
- ✕Current treatment with medications known to prolong QT interval
- ✕QTc interval prolongation >450 msec in men or >470 msec in women
- ✕Simple aspergilloma with primary indication for surgical treatment
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Voriconazole For Primary Therapy Of Proven, Chronic Bronchopulmonary Aspergillosis, In Minimally Immunocompromised Or, Non-Immunocompromised Hosts
In Brief
A Phase 3 clinical trial evaluating Voriconazole for Aspergillosis. Completed, enrolled 48 participants across 18 sites.
Detailed Summary
To evaluate the efficacy of voriconazole (VFend(R)) as first line treatment for proven chronic bronchopulmonary aspergillosis, in minimally immunocompromised or non-immunocompromised patients after 6 months of treatment i.e. chronic necrotizing pulmonary
Study Details
Timeline
Interventions
Voriconazole oral : loading dose on day 1 : 400mg/12 hours; maintenance dose 200 mg /12 hours for 6 to 12 months depending on clinical response. Alternatively, patients may start on Voriconazole, IV, for 7 days loading dose, 6mg/Kg/12 hours on day one and maintenance dose 4 mg/Kg/12 hours